Supernus (SUPN): Buy for 2026 - Sage Deal and Pipeline Make Upside Probable
Supernus is a mid-cap CNS specialist with a stabilizing cash flow profile, an active pipeline (SPN-817) and a strategic acquisition of Sage Therapeutics. The balance sheet and free cash flow generation support valuation upside from current levels. We recommend a buy with specific entry, stop and target for a 180-trading-day horizon.